Cell Therapy & Vaccines

JPT offers a large portfolio of peptide products and services supporting all development phases of new cell therapies and vaccines. These products range from discovery tools for epitope and target identification, to various peptide formats for immune monitoring and clinical grade peptides to support clinical vaccination and cell therapy trials.  Learn more

Immunology

JPT has developed a variety of unique peptide-based products allowing systematic evaluation of cellular and humoral immunity. In addition to peptide formats allowing T-cell and B-cell epitope discovery, antigen-specific T-cell stimulation and immune monitoring our clinical grade products support clinical trials for the development of new immunotherapeutics and vaccines. Learn more

Neo-Epitope Discovery & Therapy

Neo-epitopes are important targets for individualized cancer immunotherapy. JPT’s high-throughput peptide techniques enable access to customized peptide products for neo-epitope prioritization and validation, individualized therapy development and immune monitoring. Learn more

Proteomics

Proteomics is the study of a cell's protein inventory at different times by protein identification and quantification. The application of mass spectrometry and more specifically LC-MS/MS has tremendously facilitated this process. JPT developed proprietary approaches for the provision of quantified custom peptides and ready-to-use products enabling protein biomarker identification and quantitation. Learn more

COVID-19

JPT was the first company responding to the Covid-19 pandemic with the launch of a broad SARS CoV-2 genome spanning portfolio of peptide tools. The ready to use and custom peptide tools include antigen spanning PepMixTM peptide pools and PepStarTM peptide microarrays of SARS-CoV-2 wild type and mutated antigen sequences as well as antigens from other relevant corona viruses.  Learn more